Results 101 to 110 of about 53,935 (322)

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo   +11 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Comparação entre métodos clínicos e laboratoriais no diagnóstico das faringotonsilites estreptocócicas Comparative analysis of clinical and laboratory methods for diagnosing streptococcal sore throat

Jornal de Pediatria, 2005
OBJETIVOS: O diagnóstico e tratamento correto das faringotonsilites causadas pelo estreptococo beta-hemolítico do grupo A é importante, particularmente na prevenção das seqüelas não-supurativas.
Ana Gabriela P. dos Santos, Eitan N. Berezin   +1 more
doaj   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Clinical and ultrasonic features of defeat of palatine tonsils at the sick teenagers with chronic tonsillitis [PDF]

, 2006
The chronic inflammation of palatine tonsils is characterized as a multifactorial immunopathological process and takes one of the leading places among nasopharyngeal pathology, especially in children and persons of young age. The aim of our research was
Мозгова, Юлія Анатоліївна, Мозговая, Юлия Анатольевна, Mozghova, Yuliia Anatoliivna, Васильєва, Олена Геннадіївна, Васильева, Елена Геннадьевна, Vasylieva, Olena Hennadiivna   +5 more
core   +1 more source

Childhood OSAS and Obesity: Prospective Associations of Anthropometric Markers With Objective Sleep Outcomes in the CHAT Trial

Journal of Sleep Research, EarlyView.
ABSTRACT Obstructive sleep apnea syndrome (OSAS) is characterised by episodic upper airway obstruction that occurs during sleep and is common in children with obesity. The aim of the present study was to analyse the association between baseline anthropometric markers and objective sleep quality measures at follow‐up in school‐aged children with OSAS ...
Catalina Ramírez‐Contreras, Verónica Palma Elgueta, Lautaro Briones‐Suárez   +2 more
wiley   +1 more source

The Need for a Revision of Fluoroquinolone Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Feline Bacterial Isolates

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The fluoroquinolone antimicrobial agents, enrofloxacin and marbofloxacin, were approved in the United States for cats in 1990 and 2001, respectively. In 2023, revised breakpoints for testing isolates from dogs were published. These canine breakpoints are discordant with the current feline breakpoints.
Mark G. Papich, Lacie A. Gunnett, Marilyn N. Martinez   +2 more
wiley   +1 more source

Difensil Immuno Reduces Recurrence and Severity of Tonsillitis in Children: A Randomized Controlled Trial

Nutrients, 2020
Oral supplements (OS) support the immune system in fighting upper airways infection. This study aimed to analyze the effect of Difensil Immuno (DI) on the recurrence of tonsillitis and fever in children.
Arianna di Stadio, A. della Volpe, Fiammetta M Korsch, A. De Lucia, M. Ralli, F. Martines, G. Ricci   +6 more
semanticscholar   +1 more source

SOME ASPECTS OF THERAPY OF BACTERIAL INFECTIONS OF UPPER RESPIRATORY TRACT: WHAT REMAINS BEYOND CLINICAL GUIDELINES?

Медицинский совет, 2017
Тhe article is devoted to discussion of use of rational antibacterial therapy of diseases of ENTorgans. The start of antibacterial therapy is a key to success of efficiency of treatment, leads to an eradication of bacteria and decrease of risk of chronic
N. G. Berdnikova, O. Y. Klimova, D. V. Tsyganko, V. A. Ekaterinchev   +3 more
doaj   +1 more source

Zimbabwean medication use in New Zealand: The role of indigenous and allopathic substances [PDF]

, 2012
Over millennia, indigenous communities have developed distinct health systems and a range of medications. Many of these traditions have been disrupted, delegitimised and changed through processes of colonisation.
Groot, Shiloh Ann Maree, Hodgetts, Darrin, Kamutingondo, Stanley, Nikora, Linda Waimarie   +3 more
core